Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial
Posted inClinical Updates Hematology-Oncology Specialties

Oral Realgar-Indigo Naturalis Formula Matches Arsenic Trioxide Efficacy in Non-High-Risk Acute Promyelocytic Leukemia: Insights from a Multicenter Randomized Trial

A pivotal multicenter randomized trial demonstrates that oral Realgar-Indigo naturalis formula (RIF) combined with ATRA is non-inferior to arsenic trioxide (ATO) plus ATRA, providing a simplified consolidation regimen for non-high-risk APL with excellent 2-year disease-free survival and manageable toxicity.
APOLLO Trial Highlights Superior Efficacy of Arsenic Trioxide Plus ATRA in High-Risk Acute Promyelocytic Leukemia
Posted inHematology-Oncology Specialties

APOLLO Trial Highlights Superior Efficacy of Arsenic Trioxide Plus ATRA in High-Risk Acute Promyelocytic Leukemia

The phase III APOLLO trial demonstrates that arsenic trioxide combined with all-trans retinoic acid (ATRA) plus low-dose idarubicin improves event-free survival and reduces relapse rates compared to standard ATRA plus anthracycline chemotherapy in high-risk APL patients, with fewer serious adverse events.
Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes
Posted inClinical Updates Hematology-Oncology Specialties Transplantation

Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes

This study reveals that prolonged hospitalization after hematopoietic cell transplantation correlates with worse quality of life, greater symptom burden, increased depressive symptoms, and higher risk of rehospitalization and mortality within one year post-transplant.
Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up
Posted inClinical Updates Hematology-Oncology news Specialties

Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up

The 3-year follow-up of the phase III TRANSFORM study demonstrates that lisocabtagene maraleucel (liso-cel) provides superior durable efficacy and a favorable safety profile compared with standard of care in second-line relapsed/refractory large B-cell lymphoma.